Results of complex treatment of anaplastic glioma

Abstract

Anaplastic glioma is a rare disease with an unfavorable prognosis. Currently, guidelines do not provide clear recommendations for the optimal treatment of patients with anaplastic glioma, necessitating the use of individual case series to guide clinical decisionmaking. Therefore, this study aimed to review the clinical management of anaplastic gliomas, including long-term follow-up (catamnesis) and complications. Using a retrospective approach, we analyzed patients with anaplastic glioma who were treated in our institution, either with or without concomitant chemotherapy, from early 2000 until 2021. Overall survival and progressionfree survival were calculated from the time of diagnosis until death and from the initiation of radiation therapy until the detection of disease progression through MRI. Our findings indicate that the combination of surgery, radiotherapy, and chemotherapy yielded the maximum benefit in the treatment of anaplastic glioma. However, managing this aggressive tumor remains challenging, despite continuous advancements in therapeutic options. Optimal management necessitates a multidisciplinary approach and a comprehensive understanding of potential complications arising from both the disease itself and its treatment.